Our Approach

Ardelyx develops:

  • Drugs that target proteins found in the gut whose activities affect the entire body
  • Drugs that are not absorbed, enabling them to achieve systemic efficacy while avoiding systemic toxicity and side effects

What we do

Targeted Therapeutic Areas

Ardelyx has established a unique approach to drug development with programs targeting gut transporters, receptors, and enzymes

Therapeutic Areas

News

Ardelyx will present at the 22nd European Meeting on Hypertension and Cardiovascular Protection in London (UK) April 26-29, 2012


04/26/2012

RDX5791, A NON-SYSTEMIC NHE3 INHIBITOR, ALONE OR IN COMBINATION WITH ENALAPRIL, PREVENTS CARDIOVASCULAR AND RENAL DYSFUNCTION IN SALT FED RATS WITH RENAL INSUFFICIENCY

Andrew G. Spencer1, Marc Navre1, Craig F. Plato2, Kristin M. Joly2, Kevin Ida2, Eric D. Labonte1, Jeffrey W. Jacobs1 and Dominique Charmot1.

1Ardelyx, Inc., Fremont, CA, United States and 2Plato BioPharma, Inc., Westminster, CO, United States.



« back to news page